These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20705636)

  • 1. The pathogenesis of bone erosions in gouty arthritis.
    Schlesinger N; Thiele RG
    Ann Rheum Dis; 2010 Nov; 69(11):1907-12. PubMed ID: 20705636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
    Romas E
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
    Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB
    Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of osteoclasts in bone destruction in rheumatoid arthritis].
    Suzuki Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2001 Jun; 24(3):87-97. PubMed ID: 16578961
    [No Abstract]   [Full Text] [Related]  

  • 6. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL.
    Hui W; Cawston TE; Richards CD; Rowan AD
    Arthritis Res Ther; 2005; 7(1):R57-64. PubMed ID: 15642143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells as key players for bone destruction in gouty arthritis?
    Harre U; Derer A; Schorn C; Schett G; Herrmann M
    Arthritis Res Ther; 2011; 13(6):135. PubMed ID: 22136246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological characterization of receptor activator of NFkappaB ligand (RANKL) and IL-1beta expression in rodent collagen-induced arthritis.
    Weiss RJ; Erlandsson Harris H; Wick MC; Wretenberg P; Stark A; Palmblad K
    Scand J Immunol; 2005 Jul; 62(1):55-62. PubMed ID: 16092922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difficult-to-treat gouty arthritis: a disease warranting better management.
    Schlesinger N
    Drugs; 2011 Jul; 71(11):1413-39. PubMed ID: 21812506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone changes in early rheumatoid arthritis.
    Green MJ; Deodhar AA
    Best Pract Res Clin Rheumatol; 2001 Mar; 15(1):105-23. PubMed ID: 11358418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatic diseases: the effects of inflammation on bone.
    Walsh NC; Crotti TN; Goldring SR; Gravallese EM
    Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synovial fluid macrophages are capable of osteoclast formation and resorption.
    Adamopoulos IE; Sabokbar A; Wordsworth BP; Carr A; Ferguson DJ; Athanasou NA
    J Pathol; 2006 Jan; 208(1):35-43. PubMed ID: 16278818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP; Schwarz EM
    J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18.
    Inokuchi T; Moriwaki Y; Tsutsui H; Yamamoto A; Takahashi S; Tsutsumi Z; Ka T; Nakanishi K; Yamamoto T
    Cytokine; 2006 Jan; 33(1):21-7. PubMed ID: 16406656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone and joint destruction in rheumatoid arthritis: what is really happening?
    Goldring SR
    J Rheumatol Suppl; 2002 Sep; 65():44-8. PubMed ID: 12236623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone destruction by receptor activator of nuclear factor κB ligand-expressing T cells in chronic gouty arthritis.
    Lee SJ; Nam KI; Jin HM; Cho YN; Lee SE; Kim TJ; Lee SS; Kee SJ; Lee KB; Kim N; Park YW
    Arthritis Res Ther; 2011; 13(5):R164. PubMed ID: 21992185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.